Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema

Primary lymphoedema is a rare, autosomal dominant disorder that leads to a disabling and disfiguring swelling of the extremities and, when untreated, tends to worsen with time. Here we link primary human lymphoedema to the FLT4 locus, encoding vascular endothelial growth factor receptor-3 (VEGFR-3), in several families. All disease-associated alleles analysed had missense mutations and encoded proteins with an inactive tyrosine kinase, preventing downstream gene activation. Our study establishes that VEGFR-3 is important for normal lymphatic vascular function and that mutations interfering with VEGFR-3 signal transduction are a cause of primary lymphoedema.

[1]  K. Alitalo,et al.  VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. , 1997, Developmental biology.

[2]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[3]  K. Alitalo,et al.  VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. , 1996, Development.

[4]  A. Bardelli,et al.  "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. , 1997, Biochimica et biophysica acta.

[5]  Nguyen-Huu Xuong,et al.  Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with magnesium-ATP and peptide inhibitor , 1993 .

[6]  N. Ferrara.  Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[7]  Molecular basis of human piebaldism. , 1992, The Journal of investigative dermatology.

[8]  E. Huang,et al.  The kit-ligand (steel factor) and its receptor c-kit/W: pleiotropic roles in gametogenesis and melanogenesis. , 1993, Development (Cambridge, England). Supplement.

[9]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[10]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[11]  K. Alitalo,et al.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.

[12]  K. Alitalo,et al.  Signaling angiogenesis and lymphangiogenesis. , 1998, Current opinion in cell biology.

[13]  K. Robertson,et al.  Hirschsprung’s disease: genetic mutations in mice and men , 1997, Gut.

[14]  D. Birnbaum,et al.  The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. , 1993, Oncogene.

[15]  H. Hoyme,et al.  Phenotypic and genotypic heterogeneity in familial Milroy lymphedema. , 1998, Lymphology.

[16]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[17]  K. Alitalo,et al.  Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. , 1994, Oncogene.

[18]  R. Ferrell,et al.  Hereditary lymphedema: evidence for linkage and genetic heterogeneity. , 1998, Human molecular genetics.

[19]  B. Mroczkowski,et al.  Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. , 1999, Structure.

[20]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Ullrich,et al.  Kinetics of binding, endocytosis, and recycling of EGF receptor mutants , 1992, The Journal of cell biology.

[22]  T. Hunter,et al.  Receptor protein-tyrosine kinases and their signal transduction pathways. , 1994, Annual review of cell biology.

[23]  R. Spritz,et al.  Inhibition of proliferation of human melanocytes by a KIT antisense oligodeoxynucleotide: implications for human piebaldism and mouse dominant white spotting (W). , 1994, The Journal of investigative dermatology.

[24]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response , 1999, Oncogene.

[25]  S. Hanks,et al.  Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. , 1991, Methods in enzymology.

[26]  J. Barber,et al.  Unbalanced translocation in a mother and her son in one of two 5;10 translocation families. , 1996, American journal of medical genetics.

[27]  B. Pasini,et al.  RET mutations in human disease. , 1996, Trends in genetics : TIG.

[28]  M. Muenke,et al.  Fibroblast-growth-factor receptor mutations in human skeletal disorders. , 1995, Trends in genetics : TIG.

[29]  K. Alitalo,et al.  FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. , 1992, Cancer research.

[30]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[31]  A. Sigurdsson,et al.  A gene for lymphedema-distichiasis maps to 16q24.3. , 1999, American journal of human genetics.

[32]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[33]  T L Blundell,et al.  Fibroblast growth factor receptors: lessons from the genes. , 1998, Trends in biochemical sciences.

[34]  W. Wood,et al.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[36]  R. Hennekam,et al.  Repeated unbalanced offspring due to a familial translocation involving chromosomes 5 and 6. , 1998, American journal of medical genetics.

[37]  K. Pajusola,et al.  Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. , 1993, Oncogene.

[38]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Hubbard.  Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[40]  J. Zheng,et al.  Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. , 1993, Biochemistry.

[41]  V. Sotirova,et al.  Mapping of primary congenital lymphedema to the 5q35.3 region. , 1999, American journal of human genetics.

[42]  A. Jauch,et al.  Duplication within chromosome 5q characterized by fluorescence in situ hybridization. , 1999, American journal of medical genetics.